This, associated to anti–PD-1 immunotherapy prolonged median survival to 33.5 days after tumor implantation, and the survivor rate increased from 0% to approximately 40% in the combination treatment group, suggesting that this response was driven by CD8 T cells [3]. Here, CD8A is linked to neoplasm.